European Commission granted approval of darolutamide in combination with androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)
There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
GII is a leading investment firm with assets under management exceeding US$ 3.5 billion with presence across Saudi Arabia, UAE, Europe, USA and India
Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases
Surpassing 1,000 Company Owned Company Operated stores
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Subscribe To Our Newsletter & Stay Updated
